ViewRay, Inc.

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ABT has a market cap of 221.5B. Regarding current trading prices, VRAY is priced at $0.03, while ABT trades at $129.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ABT's P/E ratio is 15.95. In terms of profitability, VRAY's ROE is -0.85%, compared to ABT's ROE of +0.32%. Regarding short-term risk, VRAY is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ABT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, VRAY is priced at $0.03, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, VRAY's ROE is -0.85%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, VRAY is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BSX-PA's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BSX has a market cap of 155.9B. Regarding current trading prices, VRAY is priced at $0.03, while BSX trades at $106.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BSX's P/E ratio is 62.73. In terms of profitability, VRAY's ROE is -0.85%, compared to BSX's ROE of +0.12%. Regarding short-term risk, VRAY is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BSX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SYK has a market cap of 144.5B. Regarding current trading prices, VRAY is priced at $0.03, while SYK trades at $381.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SYK's P/E ratio is 50.13. In terms of profitability, VRAY's ROE is -0.85%, compared to SYK's ROE of +0.11%. Regarding short-term risk, VRAY is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SYK's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, MDT has a market cap of 114.4B. Regarding current trading prices, VRAY is priced at $0.03, while MDT trades at $89.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas MDT's P/E ratio is 24.74. In terms of profitability, VRAY's ROE is -0.85%, compared to MDT's ROE of +0.10%. Regarding short-term risk, VRAY is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check MDT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, EW has a market cap of 46.5B. Regarding current trading prices, VRAY is priced at $0.03, while EW trades at $78.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas EW's P/E ratio is 33.19. In terms of profitability, VRAY's ROE is -0.85%, compared to EW's ROE of +0.45%. Regarding short-term risk, VRAY is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check EW's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, DXCM has a market cap of 31.1B. Regarding current trading prices, VRAY is priced at $0.03, while DXCM trades at $77.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas DXCM's P/E ratio is 55.83. In terms of profitability, VRAY's ROE is -0.85%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, VRAY is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check DXCM's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PHG has a market cap of 25.1B. Regarding current trading prices, VRAY is priced at $0.03, while PHG trades at $26.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PHG's P/E ratio is 146.92. In terms of profitability, VRAY's ROE is -0.85%, compared to PHG's ROE of +0.03%. Regarding short-term risk, VRAY is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PHG's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, STE has a market cap of 22.3B. Regarding current trading prices, VRAY is priced at $0.03, while STE trades at $228.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas STE's P/E ratio is 36.84. In terms of profitability, VRAY's ROE is -0.85%, compared to STE's ROE of +0.09%. Regarding short-term risk, VRAY is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check STE's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PODD has a market cap of 20.1B. Regarding current trading prices, VRAY is priced at $0.03, while PODD trades at $288.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PODD's P/E ratio is 51.34. In terms of profitability, VRAY's ROE is -0.85%, compared to PODD's ROE of +0.35%. Regarding short-term risk, VRAY is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PODD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ZBH has a market cap of 17.9B. Regarding current trading prices, VRAY is priced at $0.03, while ZBH trades at $92.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ZBH's P/E ratio is 20.13. In terms of profitability, VRAY's ROE is -0.85%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, VRAY is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ZBH's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, VRAY is priced at $0.03, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ABMD's P/E ratio is 65.36. In terms of profitability, VRAY's ROE is -0.85%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, VRAY is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ABMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, VRAY is priced at $0.03, while SNN trades at $30.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SNN's P/E ratio is 32.82. In terms of profitability, VRAY's ROE is -0.85%, compared to SNN's ROE of +0.08%. Regarding short-term risk, VRAY is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SNN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, VRAY is priced at $0.03, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SWAV's P/E ratio is 78.76. In terms of profitability, VRAY's ROE is -0.85%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, VRAY is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SWAV's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ALGN has a market cap of 9.9B. Regarding current trading prices, VRAY is priced at $0.03, while ALGN trades at $138.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ALGN's P/E ratio is 23.06. In terms of profitability, VRAY's ROE is -0.85%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, VRAY is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ALGN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PEN has a market cap of 9.5B. Regarding current trading prices, VRAY is priced at $0.03, while PEN trades at $240.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PEN's P/E ratio is 64.08. In terms of profitability, VRAY's ROE is -0.85%, compared to PEN's ROE of +0.12%. Regarding short-term risk, VRAY is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PEN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, VRAY is priced at $0.03, while BIO trades at $276.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BIO's P/E ratio is -3.72. In terms of profitability, VRAY's ROE is -0.85%, compared to BIO's ROE of +0.05%. Regarding short-term risk, VRAY is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BIO's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, GMED has a market cap of 7.1B. Regarding current trading prices, VRAY is priced at $0.03, while GMED trades at $53.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas GMED's P/E ratio is 39.28. In terms of profitability, VRAY's ROE is -0.85%, compared to GMED's ROE of +0.05%. Regarding short-term risk, VRAY is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check GMED's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, VRAY is priced at $0.03, while BIO-B trades at $247.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, VRAY's ROE is -0.85%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, VRAY is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BIO-B's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, VRAY is priced at $0.03, while BRKR trades at $35.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BRKR's P/E ratio is 73.02. In terms of profitability, VRAY's ROE is -0.85%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, VRAY is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BRKR's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, IRTC has a market cap of 5.3B. Regarding current trading prices, VRAY is priced at $0.03, while IRTC trades at $164.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas IRTC's P/E ratio is -52.71. In terms of profitability, VRAY's ROE is -0.85%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, VRAY is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check IRTC's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, GKOS has a market cap of 4.9B. Regarding current trading prices, VRAY is priced at $0.03, while GKOS trades at $86.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas GKOS's P/E ratio is -53.51. In terms of profitability, VRAY's ROE is -0.85%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, VRAY is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check GKOS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, VRAY is priced at $0.03, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas NARI's P/E ratio is -59.24. In terms of profitability, VRAY's ROE is -0.85%, compared to NARI's ROE of -0.18%. Regarding short-term risk, VRAY is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check NARI's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, TMDX has a market cap of 4.1B. Regarding current trading prices, VRAY is priced at $0.03, while TMDX trades at $129.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas TMDX's P/E ratio is 60.58. In terms of profitability, VRAY's ROE is -0.85%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, VRAY is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check TMDX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ITGR has a market cap of 3.7B. Regarding current trading prices, VRAY is priced at $0.03, while ITGR trades at $107.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ITGR's P/E ratio is 45.47. In terms of profitability, VRAY's ROE is -0.85%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, VRAY is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ITGR's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, INSP has a market cap of 3.7B. Regarding current trading prices, VRAY is priced at $0.03, while INSP trades at $130.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas INSP's P/E ratio is 57.54. In terms of profitability, VRAY's ROE is -0.85%, compared to INSP's ROE of +0.10%. Regarding short-term risk, VRAY is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check INSP's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, VRAY is priced at $0.03, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AXNX's P/E ratio is -709.80. In terms of profitability, VRAY's ROE is -0.85%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, VRAY is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AXNX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PRCT has a market cap of 2.8B. Regarding current trading prices, VRAY is priced at $0.03, while PRCT trades at $49.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PRCT's P/E ratio is -29.56. In terms of profitability, VRAY's ROE is -0.85%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, VRAY is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PRCT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, LIVN has a market cap of 2.2B. Regarding current trading prices, VRAY is priced at $0.03, while LIVN trades at $42.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas LIVN's P/E ratio is -10.11. In terms of profitability, VRAY's ROE is -0.85%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, VRAY is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check LIVN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, VRAY is priced at $0.03, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas NUVA's P/E ratio is 75.00. In terms of profitability, VRAY's ROE is -0.85%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, VRAY is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check NUVA's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ATEC has a market cap of 2B. Regarding current trading prices, VRAY is priced at $0.03, while ATEC trades at $14.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ATEC's P/E ratio is -12.08. In terms of profitability, VRAY's ROE is -0.85%, compared to ATEC's ROE of -2.77%. Regarding short-term risk, VRAY is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ATEC's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, VRAY is priced at $0.03, while UFPT trades at $228.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas UFPT's P/E ratio is 27.80. In terms of profitability, VRAY's ROE is -0.85%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, VRAY is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check UFPT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, VRAY is priced at $0.03, while CNMD trades at $53.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CNMD's P/E ratio is 14.78. In terms of profitability, VRAY's ROE is -0.85%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, VRAY is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CNMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, VRAY is priced at $0.03, while AORT trades at $31.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AORT's P/E ratio is -60.67. In terms of profitability, VRAY's ROE is -0.85%, compared to AORT's ROE of -0.07%. Regarding short-term risk, VRAY is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AORT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, VRAY is priced at $0.03, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas HSKA's P/E ratio is -62.49. In terms of profitability, VRAY's ROE is -0.85%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, VRAY is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check HSKA's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SSII has a market cap of 1.2B. Regarding current trading prices, VRAY is priced at $0.03, while SSII trades at $6.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SSII's P/E ratio is -77.50. In terms of profitability, VRAY's ROE is -0.85%, compared to SSII's ROE of -1.05%. Regarding short-term risk, VRAY is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SSII's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, VRAY is priced at $0.03, while ESTA trades at $42.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ESTA's P/E ratio is -13.25. In terms of profitability, VRAY's ROE is -0.85%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, VRAY is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ESTA's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, VRAY is priced at $0.03, while AHCO trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AHCO's P/E ratio is 15.09. In terms of profitability, VRAY's ROE is -0.85%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, VRAY is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AHCO's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, VRAY is priced at $0.03, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SILK's P/E ratio is -18.96. In terms of profitability, VRAY's ROE is -0.85%, compared to SILK's ROE of -0.29%. Regarding short-term risk, VRAY is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SILK's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, VRAY is priced at $0.03, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas FNA's P/E ratio is -19.83. In terms of profitability, VRAY's ROE is -0.85%, compared to FNA's ROE of -0.36%. Regarding short-term risk, VRAY is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check FNA's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, VRAY is priced at $0.03, while TNDM trades at $15.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas TNDM's P/E ratio is -5.52. In terms of profitability, VRAY's ROE is -0.85%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, VRAY is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check TNDM's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, IART has a market cap of 956.6M. Regarding current trading prices, VRAY is priced at $0.03, while IART trades at $12.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas IART's P/E ratio is -1.88. In terms of profitability, VRAY's ROE is -0.85%, compared to IART's ROE of -0.44%. Regarding short-term risk, VRAY is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check IART's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, INMD has a market cap of 955.7M. Regarding current trading prices, VRAY is priced at $0.03, while INMD trades at $13.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas INMD's P/E ratio is 5.77. In terms of profitability, VRAY's ROE is -0.85%, compared to INMD's ROE of +0.27%. Regarding short-term risk, VRAY is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check INMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, VRAY is priced at $0.03, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CSII's P/E ratio is -20.83. In terms of profitability, VRAY's ROE is -0.85%, compared to CSII's ROE of -0.14%. Regarding short-term risk, VRAY is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CSII's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, IRMD has a market cap of 841.4M. Regarding current trading prices, VRAY is priced at $0.03, while IRMD trades at $70.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas IRMD's P/E ratio is 42.69. In terms of profitability, VRAY's ROE is -0.85%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, VRAY is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check IRMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SMLR has a market cap of 799M. Regarding current trading prices, VRAY is priced at $0.03, while SMLR trades at $34.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SMLR's P/E ratio is -14.42. In terms of profitability, VRAY's ROE is -0.85%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, VRAY is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SMLR's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SIBN has a market cap of 741.1M. Regarding current trading prices, VRAY is priced at $0.03, while SIBN trades at $18.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SIBN's P/E ratio is -27.60. In terms of profitability, VRAY's ROE is -0.85%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, VRAY is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SIBN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, VRAY is priced at $0.03, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CRY's P/E ratio is 425.71. In terms of profitability, VRAY's ROE is -0.85%, compared to CRY's ROE of -0.07%. Regarding short-term risk, VRAY is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CRY's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, VRAY is priced at $0.03, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas APEN's P/E ratio is -9.43. In terms of profitability, VRAY's ROE is -0.85%, compared to APEN's ROE of -0.85%. Regarding short-term risk, VRAY is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check APEN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AXGN has a market cap of 577M. Regarding current trading prices, VRAY is priced at $0.03, while AXGN trades at $12.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AXGN's P/E ratio is -79.19. In terms of profitability, VRAY's ROE is -0.85%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, VRAY is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AXGN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ZIMV has a market cap of 529M. Regarding current trading prices, VRAY is priced at $0.03, while ZIMV trades at $18.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ZIMV's P/E ratio is -20.84. In terms of profitability, VRAY's ROE is -0.85%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, VRAY is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ZIMV's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SRDX has a market cap of 515.2M. Regarding current trading prices, VRAY is priced at $0.03, while SRDX trades at $36.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SRDX's P/E ratio is -25.74. In terms of profitability, VRAY's ROE is -0.85%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, VRAY is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SRDX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CBLL has a market cap of 511.1M. Regarding current trading prices, VRAY is priced at $0.03, while CBLL trades at $15.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CBLL's P/E ratio is -11.31. In terms of profitability, VRAY's ROE is -0.85%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, VRAY is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CBLL's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AVNS has a market cap of 508.2M. Regarding current trading prices, VRAY is priced at $0.03, while AVNS trades at $11.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AVNS's P/E ratio is -1.33. In terms of profitability, VRAY's ROE is -0.85%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, VRAY is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AVNS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, KIDS has a market cap of 505M. Regarding current trading prices, VRAY is priced at $0.03, while KIDS trades at $20.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas KIDS's P/E ratio is -11.59. In terms of profitability, VRAY's ROE is -0.85%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, VRAY is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check KIDS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CTKB has a market cap of 461M. Regarding current trading prices, VRAY is priced at $0.03, while CTKB trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CTKB's P/E ratio is -40.44. In terms of profitability, VRAY's ROE is -0.85%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, VRAY is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CTKB's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, OFIX has a market cap of 422M. Regarding current trading prices, VRAY is priced at $0.03, while OFIX trades at $10.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas OFIX's P/E ratio is -2.91. In terms of profitability, VRAY's ROE is -0.85%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, VRAY is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check OFIX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BVS has a market cap of 410.1M. Regarding current trading prices, VRAY is priced at $0.03, while BVS trades at $6.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BVS's P/E ratio is -12.87. In terms of profitability, VRAY's ROE is -0.85%, compared to BVS's ROE of -0.21%. Regarding short-term risk, VRAY is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BVS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PACB has a market cap of 399.1M. Regarding current trading prices, VRAY is priced at $0.03, while PACB trades at $1.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PACB's P/E ratio is -0.49. In terms of profitability, VRAY's ROE is -0.85%, compared to PACB's ROE of -1.70%. Regarding short-term risk, VRAY is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PACB's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SENS has a market cap of 364.9M. Regarding current trading prices, VRAY is priced at $0.03, while SENS trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SENS's P/E ratio is -4.40. In terms of profitability, VRAY's ROE is -0.85%, compared to SENS's ROE of -7.46%. Regarding short-term risk, VRAY is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SENS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BFLY has a market cap of 346M. Regarding current trading prices, VRAY is priced at $0.03, while BFLY trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BFLY's P/E ratio is -4.66. In terms of profitability, VRAY's ROE is -0.85%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, VRAY is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BFLY's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, TMCI has a market cap of 335.9M. Regarding current trading prices, VRAY is priced at $0.03, while TMCI trades at $5.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas TMCI's P/E ratio is -6.28. In terms of profitability, VRAY's ROE is -0.85%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, VRAY is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check TMCI's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, RXST has a market cap of 317M. Regarding current trading prices, VRAY is priced at $0.03, while RXST trades at $7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas RXST's P/E ratio is -11.82. In terms of profitability, VRAY's ROE is -0.85%, compared to RXST's ROE of -0.10%. Regarding short-term risk, VRAY is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check RXST's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SNWV has a market cap of 310.6M. Regarding current trading prices, VRAY is priced at $0.03, while SNWV trades at $36.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SNWV's P/E ratio is -5.82. In terms of profitability, VRAY's ROE is -0.85%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, VRAY is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SNWV's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, VREX has a market cap of 298M. Regarding current trading prices, VRAY is priced at $0.03, while VREX trades at $7.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas VREX's P/E ratio is -6.97. In terms of profitability, VRAY's ROE is -0.85%, compared to VREX's ROE of -0.08%. Regarding short-term risk, VRAY is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check VREX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, NPCE has a market cap of 294.9M. Regarding current trading prices, VRAY is priced at $0.03, while NPCE trades at $8.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas NPCE's P/E ratio is -10.96. In terms of profitability, VRAY's ROE is -0.85%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, VRAY is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check NPCE's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, NNOX has a market cap of 293.3M. Regarding current trading prices, VRAY is priced at $0.03, while NNOX trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas NNOX's P/E ratio is -5.05. In terms of profitability, VRAY's ROE is -0.85%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, VRAY is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check NNOX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CLPT has a market cap of 282.7M. Regarding current trading prices, VRAY is priced at $0.03, while CLPT trades at $10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CLPT's P/E ratio is -13.16. In terms of profitability, VRAY's ROE is -0.85%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, VRAY is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CLPT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, QTRX has a market cap of 273.4M. Regarding current trading prices, VRAY is priced at $0.03, while QTRX trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas QTRX's P/E ratio is -4.73. In terms of profitability, VRAY's ROE is -0.85%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, VRAY is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check QTRX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CATX has a market cap of 272.4M. Regarding current trading prices, VRAY is priced at $0.03, while CATX trades at $3.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CATX's P/E ratio is -2.98. In terms of profitability, VRAY's ROE is -0.85%, compared to CATX's ROE of -0.27%. Regarding short-term risk, VRAY is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CATX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, OM has a market cap of 266.5M. Regarding current trading prices, VRAY is priced at $0.03, while OM trades at $15.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas OM's P/E ratio is -0.52. In terms of profitability, VRAY's ROE is -0.85%, compared to OM's ROE of -1.45%. Regarding short-term risk, VRAY is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check OM's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BFLY-WT has a market cap of 249.1M. Regarding current trading prices, VRAY is priced at $0.03, while BFLY-WT trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, VRAY's ROE is -0.85%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, VRAY is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BFLY-WT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CERS has a market cap of 239.9M. Regarding current trading prices, VRAY is priced at $0.03, while CERS trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CERS's P/E ratio is -12.55. In terms of profitability, VRAY's ROE is -0.85%, compared to CERS's ROE of -0.35%. Regarding short-term risk, VRAY is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CERS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, VMD has a market cap of 234.4M. Regarding current trading prices, VRAY is priced at $0.03, while VMD trades at $6.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas VMD's P/E ratio is 19.77. In terms of profitability, VRAY's ROE is -0.85%, compared to VMD's ROE of +0.10%. Regarding short-term risk, VRAY is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check VMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, MASS has a market cap of 230.2M. Regarding current trading prices, VRAY is priced at $0.03, while MASS trades at $6.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas MASS's P/E ratio is -2.89. In terms of profitability, VRAY's ROE is -0.85%, compared to MASS's ROE of -0.13%. Regarding short-term risk, VRAY is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check MASS's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, TCMD has a market cap of 224.3M. Regarding current trading prices, VRAY is priced at $0.03, while TCMD trades at $9.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas TCMD's P/E ratio is 14.62. In terms of profitability, VRAY's ROE is -0.85%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, VRAY is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check TCMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, VRAY is priced at $0.03, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas NVRO's P/E ratio is -1.91. In terms of profitability, VRAY's ROE is -0.85%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, VRAY is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check NVRO's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, MXCT has a market cap of 216.9M. Regarding current trading prices, VRAY is priced at $0.03, while MXCT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas MXCT's P/E ratio is -5.10. In terms of profitability, VRAY's ROE is -0.85%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, VRAY is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check MXCT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BWAY has a market cap of 216.8M. Regarding current trading prices, VRAY is priced at $0.03, while BWAY trades at $11.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BWAY's P/E ratio is 52.14. In terms of profitability, VRAY's ROE is -0.85%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, VRAY is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BWAY's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, VRAY is priced at $0.03, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas EYES's P/E ratio is N/A. In terms of profitability, VRAY's ROE is -0.85%, compared to EYES's ROE of -0.26%. Regarding short-term risk, VRAY is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check EYES's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, CVRX has a market cap of 197.1M. Regarding current trading prices, VRAY is priced at $0.03, while CVRX trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas CVRX's P/E ratio is -3.53. In terms of profitability, VRAY's ROE is -0.85%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, VRAY is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check CVRX's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, MGRM has a market cap of 194.9M. Regarding current trading prices, VRAY is priced at $0.03, while MGRM trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas MGRM's P/E ratio is -10.78. In terms of profitability, VRAY's ROE is -0.85%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, VRAY is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check MGRM's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, SGHT has a market cap of 169.1M. Regarding current trading prices, VRAY is priced at $0.03, while SGHT trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas SGHT's P/E ratio is -3.34. In terms of profitability, VRAY's ROE is -0.85%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, VRAY is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check SGHT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, INGN has a market cap of 167M. Regarding current trading prices, VRAY is priced at $0.03, while INGN trades at $6.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas INGN's P/E ratio is -5.40. In terms of profitability, VRAY's ROE is -0.85%, compared to INGN's ROE of -0.15%. Regarding short-term risk, VRAY is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check INGN's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, PROF has a market cap of 165.3M. Regarding current trading prices, VRAY is priced at $0.03, while PROF trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas PROF's P/E ratio is -4.55. In terms of profitability, VRAY's ROE is -0.85%, compared to PROF's ROE of -0.70%. Regarding short-term risk, VRAY is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check PROF's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, TLSI has a market cap of 158.7M. Regarding current trading prices, VRAY is priced at $0.03, while TLSI trades at $4.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas TLSI's P/E ratio is -3.80. In terms of profitability, VRAY's ROE is -0.85%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, VRAY is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check TLSI's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ELMD has a market cap of 151.7M. Regarding current trading prices, VRAY is priced at $0.03, while ELMD trades at $18.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ELMD's P/E ratio is 22.90. In terms of profitability, VRAY's ROE is -0.85%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, VRAY is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ELMD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, LNSR has a market cap of 150.1M. Regarding current trading prices, VRAY is priced at $0.03, while LNSR trades at $12.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas LNSR's P/E ratio is -2.59. In terms of profitability, VRAY's ROE is -0.85%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, VRAY is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check LNSR's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, RPID has a market cap of 145.1M. Regarding current trading prices, VRAY is priced at $0.03, while RPID trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas RPID's P/E ratio is -3.21. In terms of profitability, VRAY's ROE is -0.85%, compared to RPID's ROE of -0.56%. Regarding short-term risk, VRAY is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check RPID's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, RCEL has a market cap of 136.4M. Regarding current trading prices, VRAY is priced at $0.03, while RCEL trades at $5.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas RCEL's P/E ratio is -2.36. In terms of profitability, VRAY's ROE is -0.85%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, VRAY is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check RCEL's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, BSGM has a market cap of 134.4M. Regarding current trading prices, VRAY is priced at $0.03, while BSGM trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas BSGM's P/E ratio is -8.09. In terms of profitability, VRAY's ROE is -0.85%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, VRAY is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check BSGM's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ANIK has a market cap of 124.6M. Regarding current trading prices, VRAY is priced at $0.03, while ANIK trades at $8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ANIK's P/E ratio is -9.60. In terms of profitability, VRAY's ROE is -0.85%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, VRAY is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ANIK's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, OWLT has a market cap of 122.1M. Regarding current trading prices, VRAY is priced at $0.03, while OWLT trades at $7.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas OWLT's P/E ratio is -4.59. In terms of profitability, VRAY's ROE is -0.85%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, VRAY is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check OWLT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, AVR has a market cap of 114.5M. Regarding current trading prices, VRAY is priced at $0.03, while AVR trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas AVR's P/E ratio is -0.88. In terms of profitability, VRAY's ROE is -0.85%, compared to AVR's ROE of -2.92%. Regarding short-term risk, VRAY is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check AVR's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, LUCD has a market cap of 108.2M. Regarding current trading prices, VRAY is priced at $0.03, while LUCD trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas LUCD's P/E ratio is -0.85. In terms of profitability, VRAY's ROE is -0.85%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, VRAY is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check LUCD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, VRAY is priced at $0.03, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas ICAD's P/E ratio is -20.37. In terms of profitability, VRAY's ROE is -0.85%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, VRAY is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check ICAD's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, QIPT has a market cap of 100.4M. Regarding current trading prices, VRAY is priced at $0.03, while QIPT trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas QIPT's P/E ratio is -11.00. In terms of profitability, VRAY's ROE is -0.85%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, VRAY is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check QIPT's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, VRAY is priced at $0.03, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas HJLI's P/E ratio is N/A. In terms of profitability, VRAY's ROE is -0.85%, compared to HJLI's ROE of -0.57%. Regarding short-term risk, VRAY is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check HJLI's competition here

VRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRAY stands at 4.6M. In comparison, FONR has a market cap of 97M. Regarding current trading prices, VRAY is priced at $0.03, while FONR trades at $15.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRAY currently has a P/E ratio of -0.10, whereas FONR's P/E ratio is 12.51. In terms of profitability, VRAY's ROE is -0.85%, compared to FONR's ROE of +0.09%. Regarding short-term risk, VRAY is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAY.Check FONR's competition here